

WHAT IS CLAIMED IS CLAIMS:

1. — A crystalline form of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide having X-ray diffraction peaks at $5.4^{\circ} \pm 0.2^{\circ}$, $8.4^{\circ} \pm 0.2^{\circ}$, $18.7^{\circ} \pm 0.2^{\circ}$, $19.1^{\circ} \pm 0.2^{\circ}$, $16.1^{\circ} \pm 0.2^{\circ}$, $21.9^{\circ} \pm 0.2^{\circ}$, $10.1^{\circ} \pm 0.2^{\circ}$ degrees 2θ , and wherein the most intense peak is at 5.4 ± 0.2 degrees 2θ .

2. — A crystalline form of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide having X-ray diffraction peaks at $16.1^{\circ} \pm 0.2^{\circ}$, $22.1^{\circ} \pm 0.2^{\circ}$, $21.6^{\circ} \pm 0.2^{\circ}$, $8.8^{\circ} \pm 0.2^{\circ}$, $13.6^{\circ} \pm 0.2^{\circ}$, $23.2^{\circ} \pm 0.2^{\circ}$ degrees 2θ , and wherein the most intense peak is at 16.1 ± 0.2 degrees 2θ .

3. — A crystalline form of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide having X-ray diffraction peaks at $8.4^{\circ} \pm 0.2^{\circ}$, $5.4^{\circ} \pm 0.2^{\circ}$, $16.3^{\circ} \pm 0.2^{\circ}$, $16.1^{\circ} \pm 0.2^{\circ}$, $18.7^{\circ} \pm 0.2^{\circ}$, $21.8^{\circ} \pm 0.2^{\circ}$ degrees 2θ , and wherein the most intense peak is at 8.4 ± 0.2 degrees 2θ .

4. — A crystalline form of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide having X-ray diffraction peaks at $5.2^{\circ} \pm 0.2^{\circ}$, $15.0^{\circ} \pm 0.2^{\circ}$, $18.9^{\circ} \pm 0.2^{\circ}$, $19.0^{\circ} \pm 0.2^{\circ}$, $20.4^{\circ} \pm 0.2^{\circ}$, $12.6^{\circ} \pm 0.2^{\circ}$ degrees 2θ , and wherein the most intense peak is at 5.2 ± 0.2 degrees 2θ .

51. A crystalline form of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide having X-ray diffraction peaks at $6.2^{\circ} \pm 0.2^{\circ}$, $11.8^{\circ} \pm 0.2^{\circ}$, $12.4^{\circ} \pm 0.2^{\circ}$, $18.7^{\circ} \pm 0.2^{\circ}$, $20.1^{\circ} \pm 0.2^{\circ}$, $22.8^{\circ} \pm 0.2^{\circ}$ degrees 2θ (Type F), and wherein the most intense peak is at $18.7^{\circ} \pm 0.2$ degrees 2θ .

6. — A crystalline form of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide having X-ray diffraction peaks at $21.4^{\circ} \pm 0.2^{\circ}$, $20.7^{\circ} \pm 0.2^{\circ}$, $19.7^{\circ} \pm 0.2^{\circ}$, $17.7^{\circ} \pm 0.2^{\circ}$, $15.0^{\circ} \pm 0.2^{\circ}$, $16.3^{\circ} \pm 0.2^{\circ}$ degrees 2θ , and wherein the most intense peak is at 21.4 ± 0.2 degrees 2θ .

72. A pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide ~~any one of~~ according to Claims 1-5 and a pharmaceutically acceptable carrier.